Is ktra close to a short squeeze?

Kintara Therapeutics (KTRA) does not appear to be close to a short squeeze. Here's why:

1. Lack of Short Interest: There is no data available for the short interest expenses on short-term debt for KTRA, which makes it difficult to assess the level of short interest in the stock. However, the absence of significant interest expenses on short-term debt suggests that there may be less short sellers' interest in the stock.
2. Market Sentiment: The sentiment around KTRA does not indicate a build-up of short sellers that could trigger a short squeeze. The recent decline in short interest and the lack of bullish catalysts suggest that market participants are not taking aggressive short positions.
3. Trading Volume: The trading volume for KTRA is high, with 25.27 million shares traded on June 27, 2024. High trading volume can indicate active participation from both buyers and sellers, which can contribute to increased interest in the stock, but it does not necessarily indicate a short squeeze.
4. Technical Indicators: The stock's technical indicators, such as the Moving Averages Convergence Divergence (MACD) and the Relative Strength Index (RSI), do not show any signs of a potential short squeeze. The MACD is slightly positive, and the RSI is above the midpoint, indicating that the stock is neither overbought nor oversold.

5. Stock Performance: KTRA's recent performance does not show any signs of a short squeeze. The stock is not trading near any support or resistance levels, and the lack of significant price movement suggests that there is no strong build-up of short sellers.

In conclusion, while the possibility of a short squeeze cannot be entirely ruled out, the current market conditions and technical indicators do not strongly suggest that KTRA is poised for a short squeeze in the near future. Investors should consider these factors and their own risk tolerance before making investment decisions.